LuX-Valve procedure for severe leaking tricuspid valve
Part of Heart & circulation clinical trials.
This trial tests a minimally invasive procedure (LuX-Valve placed through a neck vein) to treat severe leaking of the tricuspid valve. It may help people who are too high-risk for open-heart tricuspid surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 50 or older when you sign consent
- Have severe (or worse) tricuspid valve leaking confirmed by an echocardiogram
- Be in NYHA heart failure class III or IV (symptoms with limited activity or at rest)
- Have good left-heart pumping (left ejection fraction 50% or higher)
- Be considered high-risk for tricuspid surgery (heart team judgment, euroSCORE II 7 or higher)
- Not have certain heart or medical problems, like high lung pressure, prior tricuspid valve replacement, or active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called the Laplace system, which replaces the tricuspid valve in your heart without open-heart surgery. It is designed for people with severe tricuspid regurgitation (a leaky heart valve) who still have symptoms despite taking medications.
This trial tests a new device called TricValve, which is placed through a catheter (a thin tube) to fix a leaky tricuspid valve on the right side of the heart. It aims to reduce blood flowing backward and improve heart failure symptoms for people who can't have open-heart surgery and haven't been helped by other catheter treatments.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new device called the Lux-Valve Plus to replace the tricuspid valve without open-heart surgery. It may help people who have severe leaking of the tricuspid valve and are too high-risk for surgery or not eligible for other non-surgical treatments.
Hear when a new Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.